Ipsen S.A. (IPSEF)
OTCMKTS · Delayed Price · Currency is USD
113.13
+9.63 (9.30%)
At close: Jun 9, 2025
Ipsen Revenue
Ipsen had revenue of 1.94B EUR in the half year ending June 30, 2025, with 19.35% growth. This brings the company's revenue in the last twelve months to 3.76B, up 11.54% year-over-year. In the year 2024, Ipsen had annual revenue of 3.57B with 8.11% growth.
Revenue (ttm)
3.76B EUR
Revenue Growth
+11.54%
P/S Ratio
2.55
Revenue / Employee
701.72K EUR
Employees
5,358
Market Cap
11.28B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.57B | 268.10M | 8.11% |
Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.09M |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
Ipsen News
- 23 days ago - Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) - GlobeNewsWire
- 4 weeks ago - Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors - Seeking Alpha
- 2 months ago - Madrigal, Ipsen, SpringWorks get EU backing for their drugs - Seeking Alpha
- 2 months ago - Ipsen S.A. - Initiation of the share buy-back program - GlobeNewsWire
- 3 months ago - Ipsen S.A. - Annual General Meeting held on 21 May 2025 - GlobeNewsWire
- 4 months ago - Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting - GlobeNewsWire
- 4 months ago - Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Ipsen S.A. reports Q1 results - Seeking Alpha